Recent advances in multinuclear complexes as potential anticancer and DNA binding agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 1, 2014, Pages 147-169

  Wang, Kehua ^a   Gao, Enjun ^b  

^a ANSHAN NORMAL UNIVERSITY   (China)

^b SHENYANG UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

Cytotoxicity; DNA binding; Metal based anticancer agents; Multinuclear complexes; Platinum complexes; Ruthenium complexes

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DIRUTHENIUM ARENE COMPLEX; KP1019; OXALIPLATIN; PLATINUM COMPLEX; RUTHENIUM COMPLEX; TRIPLATIN TETRANITRATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; COMPLEX FORMATION; CROSS LINKING; CYTOTOXICITY; DNA BINDING; HUMAN; HYDROLYSIS; INTERCALATION COMPLEX; PROTEIN DNA INTERACTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; COORDINATION COMPLEXES; CROSS-LINKING REAGENTS; DNA; DNA ADDUCTS; HUMANS; INTERCALATING AGENTS; PLATINUM; RUTHENIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899412809     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990313     Document Type: Review

References (143)

1. Rosenberg, B. In Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed.; Verlag Chemie VCH: Basel, 1999, pp. 3-27.
2. Wang, X.Y.; Guo, Z.J. In Bioinorganic medical chemistry; Alessio, E. Ed.; WILEY-VCH: Weinheim, 2011, pp. 97-139.
3. Chabner, B.A.; Roberts, T.G. Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005, 5(1), 65-72.
4. Piccart, M.J.; Lamb, H.; Vermorken, J.B. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann. Oncol., 2001, 12, 1195-1203.
5. Jamieson, E.R.; Lippard, S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev., 1999, 99, 2467-2498.
6. Deegan, P.M.; Basinger, M.A.; Jones, M.M.; Hande, K.R. Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide. Toxicology, 1996, 106(1-3), 159-166.
7. Decatris, M.P.; Sundar, S.; O'Byrne, K.J. Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat. Rev., 2004, 30(1), 53-81.
8. De Jongh, F.E.; Van Veen, R.N.; Veltman, S.J.; De Wit, R.; Van der Burg, M.E.L.; Van den Bent, M.J.; Planting, A.S.T.; Graveland, W.J.; Stoter, G.; Verweij, J. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer, 2003, 88, 1199-1206.
9. Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev., 2007, 33(1), 9-23.
10. Fuertes, M.A.; Alonso, C.; Pérez, J.M. Biochemical modulation of Cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev., 2003, 103(3), 645-662.
11. Aris, S.M.; Farrell, P.N. Towards antitumor active trans-platinum compounds. Eur. J. Inorg. Chem., 2009, 2009(10), 1293-1302.
12. Pichler, V.; Valiahdi, M.S.; Jakupec, A.M.; Arion, B.V.; Galanski, M.; Keppler, K.B. Mono-carboxylated diaminedichloridoplatinum(IV) complexes - selective synthesis, characterization, and cytotoxicity. Dalton Trans., 2011, 40, 8187-8192.
13. Harper, W.B.; Krause-Heuer, M.A.; Grant, P.M.; Manohar, M.; Garbutcheon-Singh, K.B.; Aldrich-Wright, R.J. Advances in platinum chemotherapeutics. Chem. J. Eur., 2010, 16, 7064-7077.
14. Blommaert, F.A.; Van Dijk-Knijnenburg, H.C.M.; Dijt, F.J.; Den Engelse, L.; Baan, A.R.; Berends, F.; Fichtinger-Schepman, A.M. Formation of DNA adducts by the anticancer drug carboplatin: Different nucleotide sequence preferences in vitro and in cells. Biochemistry, 1995, 34 (26), 8474-8480.
15. Clarke, M.J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev., 2003, 236, 209-233.
16. Ni, W.X.; Man, W.-L.; Cheung, M.T.W.; Sun, R.W.Y.; Shu, Y.L.; Lam, Y.W.; Che, C.M.; Lau, T.C. Osmium(VI) complexes as a new class of potential anti-cancer agents. Chem. Commun., 2011, 47, 2140-2142.
17. Gao, E.J.; Liu, L.; Zhu, M.C.; Huang, Y.; Guan, F.; Gao, X.N.; Zhang, M.; Wang, L.; Zhang, W.Z.; Sun, Y.G. Synthesis, characterization, interaction with DNA, and cytotoxic effect in vitro of new mono- and dinuclear Pd(II) and Pt(II) complexes with benzo[d]thiazol-2-amine as the primary ligand. Inorg. Chem., 2011, 50, 4732-4741.
18. Rajendiran, V.; Karthik, R.; Palaniandavar, M.; Stoeckli-Evans, H.; Periasamy, V.S.; Akbarsha, M.A.; Srinag, B.S.; Krishnamurthy H. Mixed-ligand copper(II)-phenolate complexes: Effect of coligand on enhanced DNA and protein binding, DNA cleavage, and anticancer activity. Inorg. Chem., 2007, 46, 8208-8221.
19. Wang, X.Y.; Guo, Z.J. Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents. Dalton Trans., 2008, 12, 1521-1532.
20. Kieltyka, R.; Englebienne, P.; Fakhoury, J.; Autexier, C.; Moitessier N.; Sleiman, F.H. A platinum supramolecular square as an effective G-Quadruplex binder and telomerase inhibitor. J. Am. Chem. Soc., 2008, 130 (31), 10040-10041.
21. Barnard, P.J.; Berners-Price, S.J. Targeting the mitochondrial cell death pathway with gold compounds. Coord. Chem. Rev., 2007, 251(13-14), 1889-1902.
22. Perego, P.; Caserini C; Gatti L.; Carenini, N.; Romanelli, S.; Supino, R.; Colangelo, D.; Viano I.; Leone, R.; Spinelli, S.; Pezzoni, G.; Manzotti, C; Farrell, N.; Zunino, F. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol. Pharmacol, 1999, 55(3), 528-534.
23. Manzotti, C; Pratesi, G.; Menta, E.; Di Domenico, R.; Cavalletti, E.; Fiebig, H; Kelland, R.L.; Farrell, N.; Polizzi, D.; Supino, R.; Pezzoni, G.; Zunino, F. BBR3464: A novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin. Cancer Res., 2000, 6, 2626-2634.
24. Wheate, N.J.; Collins, J.G. Multinuclear platinum complexes as anticancer drugs. Coord. Chem. Rev., 2003, 241, 133-145.
25. Qu, Y.; Farrell, N.; Kasparkova, J.; Brabec, V. DNA binding of properties of trinuclear platinum complex. J. Inorg. Biochem., 1997, 67, 174.
26. Glover, B.P.; Ashton, A.P.; Childs, J.L.; Rodger, A.; Kercher, M.; Williams, M.R.; Cola, L.D.; Pikramenou, Z. Hairpin-shaped heterometallic luminescent lanthanide complexes for DNA intercalative recognition. J. Am. Chem. Soc, 2003, 125 (33), 9918-9919.
27. Collins, J.G.; Wheate, J.N. Potential adenine and minor groove binding platinum complexes, J. Inorg. Biochem., 2004, 98(10), 1578-1584.
28. Linares, F.; Galindo, A.M.; Galli, S.; Romero, M.A.; Navarro, A.R.J.; Barea, E. Tetranuclear coordination assemblies based on half-sandwich Ruthenium(II) complexes: Noncovalent binding to DNA and cyctoxicity. Inorg. Chem., 2009, 48(15), 7413-7420.
29. Malina, J.; Hannon, J.M.; Brabec, V. Interaction of dinuclear ruthenium(JJ) supramolecular cylinders with DNA: Sequence-specific binding, unwingding, and photocleavage. Chem. Eur. J., 2008, 14, 10408-10414.
30. Chen, J.W.; Wang, X.Y.; Shao, Y.; Zhu, J.H.; Zhu, Y.G.; Li, Y.Z.; Xu, Q.; Guo, Z.J. A trinuclear copper(II) complex of 2, 4, 6-tirs(di-2-pyridylamine) -1, 3, 5-triazine shows prominent DNA cleavage activity. Inorg. Chem., 2007, 46, 3306-3312.
31. Lincoln, P.; Nordén, B. Binuclear ruthenium(II) phenanthroline compounds with extreme binding affinity for DNA. Chem. Commun., 1996, 2145-2146.
32. +. Inorg. Chem., 2001, 40, 2476-2477.
33. Liu, C.L.; Wang, L. DNA hydrolytic cleavage catalyzed by synthetic multinuclear metallonucleases. Dalton Trans., 2009, 227-239.
34. Liu, C.L.; Wang, M.; Zhang, T.L.; Sun, H.Z. DNA hydrolysis promoted by di- and multi-nuclear metal complexes. Coord. Chem. Rev., 2004, 248, 147-168.
35. Montero, I.E.; Benedetti, T.B.; Mangrum, B.J.; Oehlsen, J.M.; Qu, Y.; Farrell, P.N. Pre-associtation of polynuclear platinum anticancer agents on a protein, human serum albumin. Implications for drug design. Dalton Trans., 2007, 43, 4938-4942
36. Harris, L.A.; Yang, X.H.; Hegmans, A.; Povirk, L.; Ryan, J.; Kelland, L.; Farrell, P.N. Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Ehance-ment of cellular uptake with charge. Inorg. Chem., 2005, 44, 9598-9600.
37. 4+ (BBR 3464) with its noncovalent congeners. Mol. Pharm., 2006, 69(2), 666-672.
38. Benedetti, B.T.; Peterson, E.J.; Kabolizadeh, P.; Martínez, A.; Kipping, R.; Farrell, N.P. Effects of noncovalent platinum drug-protein interactions on drug efficacy: Use of fluorescent conjugates as probes for drug metabolism. Mol. Pharmaceutics., 2011, 8, 940-948.
39. Komeda, S.; Moulae, T.; Woods, K.K.; Chikuma, M.; Farrell, N.P.; Williarns, L.D. A third mode of DNA binding: phosphate clamps by a polynuclear platinum complex. J. Am. Chem. Soc, 2006, 128, 16092-16103.
40. Hegmans, A.; Qu, Y.; Kelland, L.R.; Roberts, J.D.; Farrell, N. Novel approaches to polynuclear platinum pro-drugs. Selective of cytotoxic platinum-spermidine species through hydrolytic cleavage of carbamates. Inorg. Chem., 2001, 40, 6108-6114.
41. Hegmans, A.; Kasparkova, J.; Vrana, O.; R. Kelland, L.; Brabec, V.; Farrell, P. N. Amide-based prodrugs of spermidine bridged dinuclear platinum. Synthesis, DNA binding, and biological activity. J. Med. Chem., 2008, 51, 2254-2260.
42. Kapp, T.; Dullin, A.; Gust, R. Mono- and polynulcear [alkylamine] platinum(U) complexes of [1, 2-bis(4-fluorophenyl) ethylenediamine] platinum(U): synthesis and investigations on cyctotoxicity, cellular distribution, and DNA and protein binding. J. Med. Chem., 2006, 49, 1182-1190.
43. Kapp, T.; Dullin, A.; Gust, R platinum(II)-dendrimer conjugates: Synthesis, and investigations on cyctotoxicity, cell distribution, platinum release, DNA, and protein binding. Bioconjugate Chem., 2010, 21, 328-337.
44. Mounir, M.; Lorenzo, J.; Ferrer, M.; Prieto, J.M.; Rossell, O.; Avilès, X.F.; Moreno, V. DNA interaction and antiproliferative behavior of the water soluble platinum supramolecular squares [(en)Pt(N-N)4(NO3)]8 (en=ethylenediamine, N-N= 4, 4-bipyridine or 1, 4-bis(4-pyridyl)tetrafluorobenzene). J. Inorg. Biochem., 2007, 101, 660-666.
45. Woodhouse, L.S.; Ziolkowski, J.E.; Rendina, M.L. Synthesis and anti-cancer activity of dinuclear platinum(U) complexes containing bis(thioalkyl) dicarba-closo-dodecaborane(12) ligands. Dalton Trans., 2005, 17, 2827-2829.
46. Zhao, Y.M.; He, W.J.; Shi, P.F.; Zhu, J.H.; Qiu, L.; Lin, L.P.; Guo, Z.J. A positively charged trinuclear 3N-chelated monofunctional platinum complex with high DNA affinity and potent cytotoxicity. Dalton Trans., 2006, 22, 2617-2619.
47. Zhu, J.H.; Zhao, Y.M.; Zhu, Y.Y.; Wu, Z.Y.; Lin, M.X.; He, W.J.; Wang, Y.; Chen, G.J.; Dong, L.; Zhang, J.F.; Lu, Y.; Guo, Z.J. DNA cross-linking patterns induced by an antitumor active trinuclear platinum complex and comparison with its dinuclear analog. Chem. Eur. J., 2009, 15, 5245-5253.
48. Wang, Y.Q.; Wang, X.Y.; Wang, J.; Zhao, Y.M.; He, W.J.; Guo, Z.J. Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin. Inorg. Chem., 2011, 50, 12661-12668.
49. Rubino, S.; Portanova, P.; Albanese, A.; Calvaruso, G.; Orecchio, S.; Fontana, G.; Stocco, G.C. Mono and polynuclear complexes of Pt(U) with polypyridyl ligands. synthesis, spectroscopic and structural characterization and cytotoxic activity. J. Inorg. Biochem., 2007, 101, 1473-1482.
50. Fan, D.M.; Yang, X.L.; Wang, X.Y.; Zhang, S.C.; Mao, J.F; Ding, J.; Lin, L.P.; Guo, Z.J. A dinuclear monofunctional platinum(U) complex with an aromatic linker show low reactivity towards glutathione but high DNA binding ability and antitumor activity. J. Biol. Inorg. Chem., 2007, 12, 655-665.
51. Zhu, J.H.; Lin, M.X.; Fan, D.M.; Wu, Z.Y.; Chen, Y.C.; Zhang, J.F.; Lu, Y.; Guo, Z.J. The role of bridging ligands in determining DNA binding ability and cross linking patterns of dinuclear platinum antitumour complexes. Dalton Trans., 2009, 48, 10889-10895.
52. Clarke, M.J.; Zhu, F.C. Frasca, D. R Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev., 1999, 99, 2511-2533.
53. Zhang, C.X.; Lippard, S.J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol., 2003, 7, 481-489.
54. Galanski, M.; Arion, V.B.; Jakupec, M.A.; Keppler, B.K. Recent developments in the field of tumor-ihibiting metal complexes. Curr. Pharm., 2003, 9, 2078-2089.
55. Wachter, E.; Heidary, D.; Howerton, B.S.; Parkin, S.; Glazer, E.C. Light acivated ruthenium complexes photobind DNA and are cytotoxic in the photodynamic therapy window. Chem. Commun., 2012, 48, 9649-9651.
56. Magennis, S.W.; Habtemariam, A.; Novakova, O.; Henry, J.B.; Meier, S.; Parsons, S.; Oswald, L.D.H.; Brabec, V.; Sadler, P.J. Dual triggering of DNA binding and fluorescence via photoactivation of a dinuclear ruthenium(U) arene complex. Inorg. Chem., 2007, 46, 5059-5068.
57. Rani-Beeram, S.; Meyer, K.; McCrate, A.; Hong, Y.; Nielsen, M.; Swavey, S. A fluorinated ruthenium porphyrin as a potential photodynamic therapy agent: Synthesis, characterization, DNA binding and melanoma cell studies. Inorg. Chem., 2008, 47, 11278-11283.
58. Smalley, K.S.M.; Contractor, R.; Haass, N.K; Kulp, A.N.; Atilla-Gokcumen, G.E.; Williams, D.S.; Bregman, H.; Flaherty, K.T.; Soengas, M.S.; Meggers, E.; Herlyn, M. An organometallic protein kinas inhibitor pharcalogically activates p53 and induces apoptosis in human melanoma cells. Cancer Res., 2007, 67, 209-217.
59. Pisani, M.J.; Weber, D.K.; Heimann, K.; Collins, J.G.; Keene, F.R. Selective mitochondrial accumulation of cyctotoxic dinuclear polypyridy ruthenium(H) complexes. Metallomics, 2010, 2, 393-396.
60. Hartinger, C.G.; Zorbas-Seifried, S.; Jakupec, M.A.; Kynast, B.; Zorbas, H.; Keppler, B.K. From bench to bedside -preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem., 2006, 100, 891-904.
61. Rademaker-Lakhai, J.M.; Bongard, D.V.D.; Pluim, D.; Beijnen, J.H.; Schellens, J.H.M. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuth, a novel ruthenium anticancer agent. Clin. Cancer Res., 2004, 10, 3717-3727.
62. Mulyana, Y.; Webber, D.K.; Buck, D.P.; Motti, C.A; Collins, J.G.; Keene, F.R. Oligonulcear polypyridyruthenium(H) complexes incorporating flexible polar and non-polar brigdes: Synthesis, DNA-binding and cytotoxicity. Dalton Trans., 2011, 40, 1510-1523.
63. Mulyana, Y.; Collins, G.; Keene, R. Synthesis, nucleic acid binding and cyctotoxicity of oligonuclear ruthenium complexes containing labile ligands. J. Incl. Phenom. Macrocycl. Chem., 2011, 71, 371-379.
64. Mendoza-Ferri, M.G.; Hartinger, C.G.; Eichinger, R.E.; Stolyarova, N.; Severin, K.; Jakupec, M.A.; Nazarov, A.A.; Keppler, B.K. Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium- arene compounds. Organometallics, 2008, 27, 2405-2407.
65. Mendoza-Ferri, M.G.; Hartinger, C.G.; Mendoza, M.A.; Groessl, M.; Egger, A.E.; Eichinger, R.E.; Mangrum, J.B.; Farrell, N.P.; Maruszak, M.; Bednarski, P.J.; Klein, F.; Jakupec, M.A; Nazarov, A.A.; Severin, K.; Keppler, B.K. Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J. Med. Chem., 2009, 52, 916-925.
66. Kandioller, W.; Hartinger, C.G.; Nazarov, A.A.; Kuznetsov, M.L.; John, R.O.; Bartel, C; Jakupec, M.A.; Arion, V.B.; Keppler, B.K. From pyrone to thiopyrone ligands-rendering maltol-derived ruthenium(H)-arene complexes that are anticancer active in vitro. Organometallics, 2009, 28, 4251-4291.
67. Peacock, A.F.A.; Melchart, M.; Deeth, R. J.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Osmium(II) and ruthenium(II) arene maltolato complexes: Rapid hydrolysis and nucleobase binding. Chem. J. Eur., 2007, 13, 2601-2613.
68. Mendoza-Ferri, M.G.; Hartinger, C.G.; Nazarov, A.A.; Eichinger, R.E.; Jakupec, M.A.; Jakupec, M.A.; Keppler, B.K. Influence of the arene ligand, the number and type of metal centers and the leaving group on the in vitro anticancer activity of polynuclear organometallic compounds. Organometallics, 2009, 28, 6260-6265.
69. Auzias, M.; Therrien, B.; Suss-Fink, G.; Stepnicka, P.; Ang, W.H.; Dyson, P.J. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: Synthesis, structure, electrochemistry, and cytotoxicity. Inorg. Chem., 2008, 47, 578-583.
70. Ibao, A.F.; Gras, M.; Therrien, B.; Suss-Fink, G.; Zava, O.; Dyson, P.J. Thiolato-bridged arene-ruthenium complexes: Synethesis, molecular structure, reactivity and anticancer activity of the dinuclear complexes [(arene)2Ru2(SR)2Cl2]. Eur. J. Inorg. Chem., 2012, 9, 1531-1535.
71. Gras, M.; Therrien, B.; Suss-Fink, G.; Zava, O.; Dyson, P.J. Thiophenolato-bridged dinuclear arene ruthenium complexes: A new family of highly cyctotoxic anticancer agents. Dalton Trans., 2010, 39, 10305-10313.
72. Fujita, M.; Yazaki, J.; Ogura, K. Preparation of a macrocylic polynuclear complex, [(en)Pd(4, 4'-bpy)]4(NO3)8, which recognizes an oraganic molecule in aqueous media. J. Am. Chem. Soc, 1990, 112, 5645-5647.
73. Gullotti, E.; Yeo, Y. Extracellularly activated nanocarriers: A new paradigm of tumor targeted drug delivery. Mol. Pharmaceutics, 2009, 6, 1041-1051.
74. Barry, N.P.E.; Edafe, F.; Therrien, B. Anticancer activity of tetracationic arene ruthenium metalla-cycles. Dalton Trans., 2011, 40, 7172-7180.
75. Mattsson, J.; Govindaswamy, P.; Renfrew, A.K.; Dyson, P.J.; Stepnicka, P.; Süss-Fink, G.; Therrien, B. Synthesis, molecular structure, and anticancer activity of cationic arene ruthenium metallarectangles. Organametallics, 2009, 28, 4350-4357.
76. Vajpayee, V.; Song, Y.H.; Yang, Y.J.; Kang, S.C.; Kim, H.; Kim, I.S.; Wang, M.; Stang, P.J.; Chi, K.W. Coordination-deriven self-assembly and anticancer activity of molecular rectangles containing octahedral ruthenium metal centers. Organametallics, 2011, 30, 3242-3245.
77. Vajpayee, V.; Song, Y.H.; Yang, Y.J.; Kang, S.C.; Cook, T.R.; Kim, D.W.; Lah, M.S.; Kim, I.S.; Wang, M.; Stang, P.J.; Chi, K.W. Selt-assembly of cationic, hetero-or homonuclear ruthinum(II) macrocyclic rectangles and their photophysical, electrochemical, and biological studies. Organametallics, 2011, 30, 6482-6489.
78. Linares, F.; Procopio, E.Q.; Galindo, M.A.; Romero, M.A.; Navarro, J.A.R.; Barea, E. Molecular architecture of redox-active half sandwich Ru(U) cyclic assemblies. Interactions with biomolecules and anticancer activity. CrystEngComm., 2010, 12, 2343-2346.
79. 6+: A Trojan house for cancer cells. Angew. Chem. Int.Ed, 2008, 47, 3773-3776.
80. Mattsson, J.; Govindaswamy, P.; Furrer, J.; Sei, Y.; Yamaguchi, K.; Süss-Fink, G.; Terrien, B. Encapsulation of aromatic molecules in hexanuclear arene ruthenium cages: A strategy to build up oragnametallic carceplex prisms with a dangling arm standing out. Organometallics, 2008, 27, 4346-4356.
81. Mattsson, J.; Zava, O.; Renfrew, A.K.; Sei, Y.; Yamaguchi, K.; Dyson, P.J.; Terrien, B. Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage. Dalton, Trans., 2010, 39, 8248-8255.
82. Zava, O.; Mattsson, J.; Terrien, B.; Dyson, P.J. Evidence for drug release from a metalla-cage delivery vector following cellular internalization. Chem. Eur. J., 2010, 16, 1428-1431.
83. Barry, N.P.E.; Zava, O.; Dyson, P.J.; Terrien, B. Excellent correlation between drug release and portal size in metalla-cage drug delivery systems. Chem. Eur. J., 2011, 17, 9669-9677.
84. Schmit, F.; Govindaswamy, P.; Zava, O.; Fink, G.S.; Jeanneret, L.J.; Terrien, B. Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy. J. Biol. Inorg. Chem., 2009, 14, 101-109.
85. Schmit, F.; Govindaswamy, P.; Zava, O.; Fink, G.S.; Ang, W.H.; Dyson, P.J.; Jeanneret, L.J.; Terrien, B. Ruthenium porphrin compounds for photodynamic therapy of cancer. J. Med. Chem., 2008, 51, 1811-1816.
86. Zhang, K.K.; Liu, H.W., Fong, T.T.H.; Chen, X.G.; Lo, K. K.W. Luminescent dendritic cyclometalated Iridium(JJI) polypyridine complexes: Synthesis, emission behavior and biological properties, Inorg. Chem., 2010, 49, 5432-5443.
87. Barry, N.P.E.; Edafe, F.; Dyson, P.J.; Therrien, B. Anticancer activity of osmium metalla-rectangles. Dalton Trans., 2010, 39, 2816-2820.
88. Kumar, S.R.; Arunachalam, S.; Periasamy, V.S.; Preethy, C.P.; Riyasdeen, A.; Akbarsha, M.A. DNA binding and biological studies of some novel water soluble polymer-copper (II) phenanthroline complexes. Eur. J. Med. Chem., 2008, 43, 2082-2091.
89. Ramakrishnan, S.; Shakthipriya, D.; Suresh, E.; Periasamy, S.V.; Akbarsha, M.A.; Palaniandavar, M. Ternary dinuclear copper(U) complexes of a hydroxybenzamide ligand with diimine coligands: the 5, 6-dmp ligand enhances DNA binding and cleavage and induces apoptosis. Inorg. Chem., 2011, 50, 6458-6471.
90. Aguirre, J.D.; Angeles-Boza, A.M.; Chouai, A.; Turro, C; Pellois, J.P.; Dunbar, K.R. Anticancer activity of heteroleptic diimine complexes of dirhodium: A study of intercalating properties, hydrophobicity and in cellulo activity. Dalton Trans., 2009, 10806-10812.
91. Herman, A.; Tanski, J.M.; Tibbetts, M.F.; Anderson, CM. Synthesis, characterization and in vitro evaluation of a potentially selective anticancer, mixed metal [Ruthenium(III)-Platinum(II)] trinulcear complex. Inorg. Chem., 2008, 47, 274-280.
92. Higgins, S.L.H.; White, T.A.; Winkel, B.S.J.; Brewer, K.J. Redox, spectroscopic, and photophysical properties of Ru-Pt mixed-metal complexes incorporating 4, 7-diphenyl-1, 10-phenanthroline as efficient DNA binding and photocleaving agents. Inorg. Chem., 2011, 50, 463-470.
93. Prussin, A.J.; Zhao, S.L.; Jain, A.; Winkel, B.S.J.; Brewer, K.J. DNA interaction studies of tridentate bridged Ru-Pt mixed-metal supramolecules. J. Inorg. Biochem., 2009, 103, 427-431.
94. Dong, X.D.; Wang, X.Y.; Lin, M.X.; Yang, X.L.; Guo, Z.J. Promotive effect of the platinum moiety on the DNA cleavage activity of Copper-based artificial nucleases. Inorg. Chem., 2010, 49, 2541-2549.
95. Wenzel, W.; Bertrand, B.; Eymin, M.J.; Comte, V.; Harvey, J.A.; Richard, P.; Groessl, M.; Zava, O.; Amrouche, H.; Harvey, P.D.; Gendre, P.L.; Picquet, M.; Casini, A. Multinuclear cytotoxic metallodrugs: Physicochemical characterization and biological properties of novel heteronuclear gold-titanium complexes. Inorg. Chem., 2011, 50, 9472-9480.
96. Pelletier, F.; Comte, V.; Massard, A.; Wenzel, M.; Toulot, S.; Richard, P.; Picquet, M.; Gendre, P.L.; Zava, O.; Edafe, F.; Casini, A.; Dyson, P.J. Development of bimetallic titanocene-ruthenium-arene complexes as anticancer angents: Relationships between structural and biological properties. J. Med. Chem., 2010, 53, 6923-6933.
97. Jung, Y.; Lippard, S.J. Direct cellular responses to platinum induced DNA damage. Chem. Rev., 2007, 107, 1387-1407.
98. Mangrum, B.J.; Farrell, P.N. Excursions in polynuclear platinum DNA binding. Chem. Commun., 2010, 46, 6640-6650.
99. Kloster, M.B.G.; Hannis, J.C.; Muddiman, D.C.; Farrell, N. Consequences of nucleic acid conformation on the binding of a trinuclear platinum drug. Biochemistry, 1999, 38, 14731-14737.
100. Kasparkova, J.; Zehnulova, J.; Farrell, N.; Brabec, V. DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. J. Biol.Chem., 2002, 277, 48076-48086.
101. Qu, Y.; Sarsdal, J.N.; Tran, M.C.; Farrell, N. Cooperative effects in long-range 1, 4 DNA DNA interstrand cross-links formed by polynuclear platinum complexes: An unexpexted syn orientation of ademine bases outside the binding sites. J. Biol. Inorg. Chem., 2003, 8, 19-28.
102. Kaspárková, J.; Nováková, O.; Vrána, O.; Farrell, N.; Brabec, V. Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross linking. Biochemistry, 1999, 38, 10997-11005.
103. Farrell, N.; Appleton, T.G.; Qu, Y.; Roberts, J.D.; Soares Fontes, A.P.; Skov, K.A.; Wu, P.; Zou, Y. Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. Biochemistry, 1995, 34, 15480-15486.
104. McGregor, T.D.; Balcarova, Z.; Qu, Y.; Tran, M.; Zaludová, R.; Brabec, V.; Farrell, N. Squence dependent conformational changes in DNA induced by polynuclear platinum complexes. J. Inorg. Biochem., 1999, 77, 43-46.
105. Kaspárková, J.; Mellish, K.J.; Qu, Y.; Brabec, V.; Farrell, N. Site specific (dGpG) intrastrand cross links formed by dinuclear platinum complexes. Bending and NMR studies. Biochemisty, 1996, 35, 16705-16713.
106. Zaludová, R.; Zákovská, A.; Kaspárková, J.; Balcarová, Z.; Kleinwächther, V.; Vrána, O.; Farrell, N.; Brabec, V. DNA interactions of bifunctional dinuclear platinum(II) antitumor agents. Eur. J. Biochem., 1997, 246, 508-517.
107. Hofr, C; Farrell, N.; Brabec, V. Thermodynamic properties of duplex DNA containing a site specific d(GpG) intrastrand crosslink formed by an antitumor dinuclear platinum complex. Nucl. Acids Res., 2001, 29, 2034-2040.
108. Kasparkova, J.; Farrell, N.; Brabec, V. Sequence specificity, conformation, and recognition by HMG1 protein of major interstrand cross links of antitumor dinuclear platinum complexes. J. Biol. Chem., 2000, 275, 15789-15798.
109. Moriarity, B.; Nováková, O.; Farrell, N.; Brabec, V.; Kaspárková, J. 1, 2-GG intrastrand cross link of antitumor dinuclear bifunctional platinum compound with spermidine linker inhibits DNA polymerization more effectively than the cross link of conventional cisplatin. Arch. Biochem. Biophys., 2007, 459, 264-272.
110. Zerzankova, L.; Suchankova, T.; Vrana, O.; Farrell, N.P.; Brabec, V.; Kasparkova, J. Conformation and recognition of DNA modified by a new antitumor dinuclear platinum H complex resistant to decomposition by sulfur nucleophiles. Biochem. Pharm., 2010, 79, 112-121.
111. Florian, J.; Kasparkova, J.; Farrell, N.P.; Brabec, V. Thermodynamic stability and energetics of DNA duplexes containing major intrastrand cross-links of second generation antitumor dinuclear PtH complexes. J. Biol. Inorg. Chem., 2012, 17, 187-196.
112. McGregor, T.D.; Hegmans, A.; Kaspárková, J.; Neplechová, K.; Nováková, O.; Penazová, H.; Vrána, O.; Brabec, V.; Farrell, N. A comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase H clinical agent BBR3464. J. Biol. Inorg. Chem., 2002, 7, 397-404.
113. Brabec, V.; Kaspárková, J.; Vrána, O.; Nováková, O.; Cox, J.W.; Qu, Y.; Farrell, N. DNA modifications by a novel bifunctional trinuclear platinum phase I anticacer agent. Biochemistry, 1999, 38, 6781-6790.
114. Zenzankova, L.; Kostrhunova, H.; Vojtiskova, M.; Novakova, O.; Suchankova, T.; Lin, M.X.; Guo, Z.J.; Kasparkova, J.; Brabec, V. Mechanistic insights into antitumor effects of new dinuclear cis Pt complexes containing aromatic linkers. Biochem. Pharm., 2010, 80, 344-351.
115. Malina, J.; Kasparkova, J.; Farrell, N.P.; Brabec, V. Walking of antitumor bifunctinal trinuclear PtH complex on double-helical DNA. Nucl. Acids Res., 2011, 39, 720-728.
116. Hegmans, A.; Berners-Price, S.J.; Davies, M.S.; Thomas, D.S.; Humphreys, A.S.; Farrell, N. Long range 1, 4 and 1, 6-interstrand cross links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross link formation as well as adduct structure. J. Am. Chem. Soc, 2004, 126, 2166-2180.
117. Cox, J.W.; Berners-Price, S.J.; Davies, M.S.; Qu, Y.; Farrell, N. Kinetic analysis of the stepwise formation of a long range DNA interstrand cross link by a dinuclear platinum antitumor complex: evidince for aquated intermediates and formation of both kinetically and thermodynamically controlled conformers. J. Am. Chem. Soc, 2001, 123, 1316-1326.
118. Ruhayel, R.A.; Moniodis, J.J.; Yang, X.; Kasparkova, J.; Brabec, V.; Berners-Price, S.J.; Farrell, N. Factors affecting DNA-DNA interstrand cross-links in the antiparallel 3'-3' sense: A comparison with 5'-5' directional isomer. Chem. Eur. J., 2009, 15, 9365-9374.
119. Malina, J.; Farrell, N.P.; Brabec, V. DNA interstrand cross-links of an antitumor trinuclear platinum(II) complex: Thermodynamic analysis and chemical probing. Chem. Asian J., 2011, 6, 1566-1574.
120. 6+ -DNA adducts with various cross linking mode. Nucl. Acids Res., 2009, 37, 5930-5942.
121. Marini, V.; Kasparkova, J.; Novakova, O.; Scolaro, L.M.; Romeo, R.; Brabec, V. Biophysical analysis of natural, double helical DNA modified by a dinuclear platinum (II) organometallic compound in a cell free medium. J. Biol. Inorg. Chem., 2002, 7, 725-734.
122. Mlcouskova, J.; Kasparkova, J.; Suchankova, T.; Komeda, S.; Brabec, V. DNA conformation and repair of polymeric natural DNA damaged by antitumor azolato brigdged dinuclear platinum H complex. J. Inorg. Biochem., 2012, 114, 15-23.
123. Teletchéa, S.; Komeda, S.; Teuben, J.M.; Elizondo-Riojas, M.A.; Reedijk, J.; Kozelka, J. A pyrazolato-bridged dinuclear platinum(II) complex induces only minor distortions upon DNA binding. Chem. Eur. J., 2006, 12, 3741-3753.
124. Komeda, S.; Bombard, S.; Perrier, S.; Reedijk, J.; Kozelka, J. Kinetic study of azole-bridged dinuclear platinum(II) complexes reacting with a hairpin stabilized double stranded oligonucleotide. J. Inorg. Biochem., 2003, 96, 357-366.
125. Olivova, R.; Stepankova, J.; Muchova, T.; Novohradsky, V.; Novakova, O.; Vrana, O.; Kasparkova, J.; Brabec, V. Mechanistic insights into toxic effects of a benzotriazolate bridged dinuclear platinum compound in tumor cells. Inorg. Chim. Acta, 2012, 393, 204-211.
126. Mlcouskova, J.; Malina, J.; Novohradsky, V.; Kasparkova, J.; Komeda, S.; Brabec, V. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear PtH complex. Biochim. Biophys. Acta, 2012, 1820, 1502-1511.
127. Olivova, R.; Kasparkova, J.; Vrana, O.; Vojtiskova, M.; Suchankova, T.; Novakova, O.; He, W.J.; Guo, Z.J.; Brabec, V. Unique DNA binding mode of antitumor trinuclear tridentate platinum(H) compound. Mol. Pharmaceutics, 2011, 8, 2368-2378.
128. Nováková, O.; Nazarov, A.A.; Hartinger, C.G.; Keppler, B.K.; Brabec, V. DNA interaction of dinclear Ru arene antitumor complexes in cell-free media. Biochem.Pharmacol, 2009, 77, 364-374.
129. Muchova, T.; Quintal, S.M.; Farrell, N.P.; Brabec, V.; Kasparkova, J. Antitumor bifunctional dinuclear PtH complex BBR3535 forms interduplex DNA cross links under molecular crowding conditions. J. Biol. Inorg. Chem., 2012, 17, 239-245.
130. Barker, S.; Weinfeld, M.; Murray, D. DNA protein crosslinks: their induction, repair and biological consequences. Mutation Res., 2005, 589, 111-135.
131. Ide, H.; Shoulkamy, M.I.; Nakano, T.; Miyamoto-Matsubara, M.; Salem, A.M.H. Repair and biochemical effects of DNA-protein crosslinks. Mutation Res., 2011, 711, 113-122.
132. Zwelling, L.A.; Anderson, T.; Kohn, K.W. DNA-protein and DNA interstrand cross-linking by cis- and trans- platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res., 1979, 39, 365-369.
133. Chválová, K.; Brabec, V.; Kaspárková, J. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucl. Acids Res., 2007, 35(6), 1812-1821.
134. Novakova, O.; Kasparkova, J.; Malina, J.; Natile, G.; Brabec, V. DNA-protein cross-linking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans gometry in platinum antitumor complexes. Nucl. Acids Res., 2003, 31(22), 6450-6460.
135. Farrell, N.; Povirk, L.F.; Dange, Y.; DeMasters, G.; Gupta, M.S.; Kohlhagen, G.; Khan, Q.A.; Pommier, Y.; Gewirtz, D.A. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem. Pharm., 2004, 68, 857-866.
136. Houten, B.V.; Illenye, S.; Qu, Y.; Farrell, N. Homodinuclear (Pt, Pt) and heterodinclear (Ru, Pt) metal compounds as DNA-protein cross-linkings agents: potential suicide DNA lesions. Biochemistry, 1993, 32, 11794-11801.
137. Kloster, M.; Kostrbunova, H.; Zaludov, R.; Malina, J.; Kasparkova, J.; Brabec, V.; Farrell, N. Trifuctional dinuclear platinum complexes as DNA- protein cross-linking agents. Biochemistry, 2004, 43, 7776-7786.
138. Brabec, V.; Christofis, P.; Slámová, M.; Kostrhunová, Nováková, Najajreh, Y.; Gibson, D; Kaspárková, J. DNA interations of new cytotoxic tetrafunctional dinuclear platinum complex trans, trans-[{PtCl(NH3)}2(piperazine)]. Biochem. Pharm., 2007, 73, 1887-1900.
139. Wheate, N.J.; Brodie, C.R.; Collins, J.G.; Kemp, S.; Aldrich-Wright, J.R. DNA intercalators in cancer therapy: Organic and inorganic drugs and their spectroscopic tools of analysis. Mini. Rev. Med. Chem., 2007, 7, 627-648.
140. Blackburn, G. M., Gait, M. J., Ed. In Nucleic Acids in Chemistry and Biology, 2nd ed.; IRL Press: Oxford University, 1996, pp 352-357.
141. 2+ dimmer. J. Am. Chem. Soc, 1999, 121, 10846-10847.
142. Nazif, M.A.; Bangert, J.A.; Ott, I.; Gust, R.; Stoll, R.; Sheldrick, W.S. Dinuclear organoiridium(III) mono- and bis-intercalators with rigid bridging ligands: Synthesis, cystotoxicity and DNA binding. J. Inorg. Biochem., 2009, 103, 1405-1414.
143. Kokoschka, M.; Bangert, J.A.; Stoll, R.; Sheldrick, W.S. Sequence-selective organoiridium DNA bis-intercalators with flexible dithiaalkane linker chains. Eur. J. Inorg. Chem., 2010, 1507-1515.